Medicus Pharma

What Medicus Pharma does

Medicus Pharma Ltd. (NASDAQ: MDCX) is a Toronto-based, Canadian-incorporated clinical-stage biotechnology company developing non-systemic therapies for dermatologic and endocrine indications. Its two lead assets are SkinJect, a dissolvable microneedle array (D-MNA) delivering 5-fluorouracil for the treatment of basal cell carcinoma, and Teverelix, a GnRH antagonist targeting advanced prostate cancer, endometriosis, and benign prostatic hyperplasia that was added via the September 2025 acquisition of Antev Ltd. The lead SkinJect program reported positive Phase 2 topline data in March 2026 with 73% clinical clearance in the 200µg cohort, while Teverelix received an FDA Study May Proceed letter in February 2026 to commence a Phase 2b trial in advanced prostate cancer, with Orphan Drug Designation and Rare Pediatric Disease Designation pending.

The company operates a pre-revenue, R&D-driven business model with no marketed products and no recurring customer revenue. Future monetization is expected to come from out-licensing or partnering SkinJect and Teverelix to larger pharmaceutical companies, supplemented by potential milestone and royalty streams. To date, operations have been financed almost entirely by equity, warrant, debenture, and structured-financing transactions — including a $4.93M raise in 2023, $7M in May 2025, an $8M debenture in September 2025, $5.1M and $15.3M ATM-related raises in December 2025, and a $22M structured facility in May 2026 — with FY2025 net losses of $35.4M and Q1 2026 net losses of $9.0M. Headcount sits in the 11–50 range, and the company has disclosed a going-concern doubt and Nasdaq minimum bid price non-compliance in April 2026. Strategic ancillary initiatives include a January 2026 Reliant AI partnership for clinical data analytics, a UK clinical footprint, and a UAE expansion tied to a national genome program, but these remain early-stage and do not yet contribute revenue.

Name

Medicus Pharma

Legal name

Medicus Pharma Ltd.

Website

https://medicuspharma.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicus Pharma is a Toronto-based, clinical-stage biotech developing a dissolvable microneedle 5-FU therapy (SkinJect) for basal cell carcinoma and a GnRH antagonist (Teverelix) for prostate cancer, endometriosis, and BPH, with no current product revenue.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pre-revenue (clinical-stage): Medicus Pharma is a clinical-stage biotech with no approved products; reported FY2025 net loss of $35.4 million and Q1 2026 net loss of $9.0 million. Anticipated future revenue is expected to come from out-licensing of SkinJect and Teverelix assets to established pharmaceutical companies for late-stage development and commercialization.
2. Capital markets financing (non-operating): Company funds operations through capital raises including an Equity Distribution Agreement / ATM program up to $50 million, $22 million structured financing facility, $8 million non-dilutive debenture, warrant inducements, and SEPA facilities. Operations are not yet revenue-generating.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Medicus Pharma is a precision-guided, clinical-stage biotech company that acquires and accelerates the development of novel therapeutic assets through Phase 2 proof-of-concept, then pursues licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization. Its pipeline includes SkinJect (a Doxorubicin Microneedle Array patch for basal cell carcinoma and Gorlin Syndrome) and Teverelix (a long-acting GnRH antagonist for advanced prostate cancer, acute urinary retention, and endometriosis).

Product overview

Medicus Pharma operates a precision-guided biotech portfolio model: a single parent platform (Medicus Pharma Ltd., NASDAQ: MDCX) that acquires and accelerates clinical-stage therapeutic assets through Phase 2 proof-of-concept before seeking licensing or strategic partnerships for late-stage development and commercialization. The core portfolio currently consists of two therapeutic programs — SkinJect (D-MNA, a doxorubicin microneedle array patch for basal cell carcinoma and Gorlin Syndrome, advanced through subsidiary SkinJect Inc.) and Teverelix (a long-acting GnRH antagonist acquired via Antev Ltd. for advanced prostate cancer, acute urinary retention, and endometriosis). These clinical assets are wrapped by an emerging AI-enabled drug development capability, including an agentic AI-enabled clinical platform and a Reliant AI co-developed clinical data analytics platform for site selection, patient stratification, and enrollment forecasting, intended to compress timelines across the portfolio.

Differentiator

Problem solved

Functional benefit

Brands

• SkinJect: Portfolio company of Medicus Pharma developing a Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma and Gorlin Syndrome.
• Antev Ltd

Products and services

• SkinJect (D-MNA: Doxorubicin Microneedle Array) Investigational, non-surgical drug-device combination delivering doxorubicin directly into tumors via a dissolvable microneedle array patch for the non-invasive treatment of nodular basal cell carcinoma, including patients with Gorlin Syndrome (NBCCS). Advanced through wholly-owned subsidiary SkinJect Inc.
• Teverelix Long-acting next-generation GnRH antagonist in development for advanced prostate cancer (including a cardiovascular high-risk population), acute urinary retention associated with benign prostatic hyperplasia, and endometriosis. Acquired via the September 2025 acquisition of UK-based Antev Limited.
• PRECISION-E2 (Teverelix Endometriosis Phase 2a) Phase 2a genomics-enabled clinical trial program evaluating Teverelix in women with symptomatic endometriosis across multiple UAE sites, integrating the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy.

Quantifiable outcome

• Phase 2 SkinJect 200µg cohort: 73% clinical clearance and 40% histological clearance at Day 57 (90 patients)
• +4 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• UAE Genome Program (Emirati Genome Program)coreStrategic or Co-development Partner · 11 June 2026Collaboration enabling the PRECISION-E2 Phase 2a genomics-enabled clinical trial evaluating Teverelix in women with symptomatic endometriosis in the UAE. The trial leverages the Emirati Genome Program to explore how genetic variation influences response to hormonal therapy, representing one of the first prospective studies integrating genomic profiling with hormonal modulation in endometriosis.
• House Energy & Commerce Committee (US Congress)coreOthers · 27 April 2026CEO Dr. Raza Bokhari and leadership team met with senior members of the House Energy & Commerce Committee on Capitol Hill (including Chair Brett Guthrie) in collaboration with the Gorlin Syndrome Alliance to advocate for Orphan Drug Designation and Registrational IND approval for SkinJect in Gorlin Syndrome. Engagement targets key committee chairs and caucus co-chairs shaping US rare disease policy.
• New to The StreetcoreGTM or Marketing Partner · 7 April 202612-part national media series highlighting SkinJect and Teverelix platforms, broadcast on Bloomberg Television across the US, MENA, and Latin America. Builds on an earlier six-part media series (Feb 2026) to raise Medicus' visibility among investors and healthcare communities.
• Omics LabsminorStrategic or Co-development Partner · 1 April 2026Collaboration to explore development of Teverelix for endometriosis in the United Arab Emirates. Positioned as part of the broader plan to advance Teverelix as potentially the first long-acting injectable GnRH antagonist for women's health indications.
• Brookline Capital MarketsminorGTM or Marketing Partner · 18 March 2026Hosted fireside chat featuring Medicus Pharma discussing positive Phase 2 SkinJect topline results (73% clinical clearance in 200-µg arm). Biotechnology equity research analyst engagement to communicate clinical and corporate developments to investors.
• Reliant AI Inc.coreStrategic or Co-development Partner · 22 December 2025Non-binding letter of intent to jointly develop an AI-powered clinical data analytics platform for clinical trial execution. Initial one-year, milestone-based engagement capped at $200,000 focuses on dynamic site selection, patient stratification, and enrollment forecasting for an upcoming Teverelix clinical study planned for 2026. Potential expansion to a larger late-stage study in 2028. Platform integrates Reliant's AI technology with Medicus' clinical, operational, and proprietary datasets.
• Helix NanotechnologiescoreStrategic or Co-development Partner · 1 December 2025Non-binding Memorandum of Understanding (MoU) with Helix Nanotechnologies referenced in connection with advancing Medicus' therapeutics and microneedle technology programs. Specific scope and financial terms not disclosed in available sources.
• Gorlin Syndrome AlliancecoreStrategic or Co-development Partner · 29 October 2025Collaboration to pursue a compassionate use / expanded access pathway for SKINJECT in patients with Gorlin Syndrome through the FDA's Expanded Access IND Program. Joint effort to collect real-world safety data to support future regulatory filings and expand clinical trials, while also collaborating on Capitol Hill advocacy for orphan drug designation.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sol-Gel Technologies: Clinical and commercial dermatology company developing topical therapies for skin conditions including basal cell carcinoma (with generic and branded assets). Highly comparable to Medicus given its focus on BCC treatment and recent clinical pipeline activity.
• Biofrontera Inc. Commercial-stage dermatology company marketing Ameluz and BF-RhodoLED for actinic keratosis and exploring basal cell carcinoma indications. Comparable to Medicus as a US-focused dermatology player targeting non-melanoma skin cancer with a procedural/drug-device approach.
• Myovant Sciences (Sumitomo Pharma / Pfizer): Developer of Orgovyx (relugolix), an FDA-approved oral GnRH antagonist for advanced prostate cancer. Direct competitor to Teverelix in the long-acting GnRH antagonist category for prostate cancer, with established commercial infrastructure.
• Tolmar Pharmaceuticals: Specialty pharmaceutical company with Eligard (leuprolide) and supplying a long-acting injectable GnRH agonist in prostate cancer. Comparable to Medicus in the hormonal prostate cancer therapy space where Teverelix is positioning itself.

Broad incumbents

• Sun Pharmaceutical Industries (Levulan/Kerastick): Large global pharmaceutical company with an approved photodynamic therapy (Levulan/kerastick) used in BCC treatment. Relevant comparable as an incumbent offering an established non-surgical BCC modality against which SkinJect would compete or pair.
• PellePharm (a LEO Pharma company): Developed patidegib (a hedgehog pathway inhibitor) for Gorlin Syndrome under LEO Pharma. Most direct prior competitor in Gorlin Syndrome BCC treatment, providing historical context for the regulatory and clinical bar Medicus must clear with SkinJect.

Emerging players

• Vaxxas: Clinical-stage company developing dissolvable microarray patch technology for vaccine and therapeutic delivery. Comparable to Medicus from a microneedle/drug-device delivery platform perspective (relevant to SkinJect D-MNA).
• Aclaris Therapeutics: Clinical-stage dermatology therapeutics company developing novel topical and immuno-modulatory therapies for skin diseases including rare dermatologic indications. Comparable to Medicus as a small-cap clinical-stage dermatology biotech pursuing niche indications.
• Krystal Biotech: Commercial-stage genetic medicines company that leveraged Orphan Drug and Rare Pediatric Disease Designations to commercialize Vyjuvek. Highly comparable as a small-cap biotech that successfully translated rare-disease designations into commercial value, illustrating the regulatory pathway Medicus is pursuing.

Others

• Reliant AI Inc. AI-driven clinical data analytics platform partner co-developing Medicus's site selection, patient stratification, and enrollment forecasting capability. Relevant as the technology partner enabling Medicus's 'agentic AI-enabled drug development' narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/MedicusLtd
• YouTubeyoutube.com/@MedicusPharmaLtd
• LinkedInlinkedin.com/company/medicus-pharma-ltd

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicus Pharma